Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Uterine fibroids (UFs) may grow continuously in some postmenopausal women, most likely because of the presence of small fibroids or obesity.

Major finding: The median growth rate of UFs was 12.9% every 6 months, with 79.5% of the UFs showing enlargement and 20.5% regressed spontaneously. The median growth rate of UFs was significantly higher in obese and overweight women than those with normal weight (P = .043). The growth was rapid in tumors with a diameter less than 3 cm vs greater than or equal to 5 cm (28.8% vs 9.1% in 6 months; P = .015).

Study details: Findings are from a retrospective longitudinal study including 102 postmenopausal women with 132 surgically identified UFs who had received at least 2 transvaginal ultrasound examinations in a 6-month interval.

Disclosures: This study was supported by the Capital Medical University Advanced Discipline Construction Project of Clinical Medicine. The authors declared no conflict of interests.

Source: Shen M et al. Menopause. 2021 Sep 6. doi: 10.1097/GME.0000000000001846.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Women with uterine leiomyoma (UL) appeared to be at a higher risk of developing endometriosis. The risk increased further if UL was present along with comorbidities like infertility or endometritis.

Major finding: Patients with UL vs control participants were at a higher risk of developing endometriosis (adjusted hazard ratio [aHR], 6.44; P less than .001). The comorbidities significantly associated with risk for endometriosis were tube-ovarian infection (aHR, 2.86; P = .01), endometritis (aHR, 1.14; P < .001), infertility (aHR, 1.26; P <  .001), and allergic diseases (aHR, 1.11; P < .001).

Study details: Findings are from a large-scale nationwide cohort including 31,239 women with UL matched with 1,24,956 control participants and followed up for 14 years.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Lin KY et al. PLoS One. 2021 Aug 26. doi: 10.1371/journal.pone.0256772.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Proton pump inhibitor (PPI) use was positively associated with the risk of developing psoriasis.

Major finding: Compared with PPI use of 30 or less cumulative defined daily doses (cDDD), PPI use of 120-365 (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.31-1.76) and higher than 365 (aOR, 1.54; 95% CI, 1.22-1.93) was associated with a significantly higher risk for psoriasis. Lansoprazole (OR, 1.25; 95% CI, 1.11-1.41), but not pantoprazole, esomeprazole, rabeprazole, or omeprazole, significantly contributed to psoriasis risk.

Study details: Findings are from a nationwide nested case-control study including 5,756 patients with prior exposure to PPIs, of which 2,878 patients had psoriasis.

Disclosures: The study was supported by Taipei Veterans General Hospital and Ministry of Science and Technology, Taiwan. The authors declared no potential conflict of interests.

Source: Li CY et al. Dermatology. 2021 Sep 2. doi: 10.1159/000517515.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Patients with psoriasis displayed enhanced susceptibility to psychiatric diseases with the highest risk for those with severe psoriasis, necessitating the simultaneous treatment of both conditions.

Major finding: Patients with psoriasis were at a higher risk for depression (adjusted hazard ratio [aHR], 1.18; 95% confidence interval [CI], 1.09-1.26), anxiety disorders (aHR, 1.16; 95% CI, 1.08-1.26), and somatoform disorders (aHR, 1.21; 95% CI, 1.08-1.34) than healthy controls. Patients with moderate-to-severe vs. mild disease showed a higher risk of developing depression (aHR, 1.28; 95% CI, 1.07-1.54 vs aHR, 1.17; 95% CI, 1.07-1.27) and somatoform disorders (aHR, 1.60; 95% CI, 1.26-2.03 vs aHR, 1.13; 95% CI, 1.00-1.28).

Study details: The data come from a nationwide, prospective cohort study including 10,868 patients with psoriasis and 1,620,055 nonpsoriasis patients followed up for a maximum period of 15 years.

Disclosures: The study was sponsored by Ministry of Health and Welfare, Ministry of Science and Information and Communications Technology, Korea Centers for Disease Control and Prevention, and Ministry of Education. The authors declared no potential conflict of interests.

Source: Oh J et al. J Dermatol. 2021 Aug 30. doi: 10.1111/1346-8138.16115.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: Secukinumab caused substantial and sustained skin clearance irrespective of prior treatment, leading to high patient satisfaction in patients with moderate-to-severe plaque psoriasis.

Major finding: Overall, 82.3% of patients endorsed the skin clearing effect of secukinumab at 6 months, which persisted through 12 (81.7%), 18 (83.3%), and 24 (81.4%) months. Biologic-experienced/naive and systemic-experienced/naive patients showed similar results. Of those dissatisfied at baseline, 77.9% of patients reported satisfaction at 6 months, which lasted through 12 (74.4%), 18 (82.8%), and 24 (71.4%) months.

Study details: The study included 3,680 patients aged 18 years or above with moderate-to-severe plaque psoriasis who received secukinumab.

Disclosures: The study was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. AW Armstrong and PS Yamauchi declared serving as an investigator/consultant/advisor/speaker for various organizations. D Patil, E Levi, and E Nguyen declared being employees of Novartis Pharmaceuticals Corporation.

Source: Armstrong AW et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00599-5.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.

Key clinical point: For a certain body mass index (BMI), abdominal subcutaneous adipose tissue (ASAT) was negatively associated with coronary atherosclerosis burden in men with psoriasis.

Major finding: After adjusting for traditional risk factors and each patient's BMI, ASAT was negatively associated with noncalcified and lipid-rich necrotic core burden in men (β, −0.17; P = .03; β, −0.20; P = .03, respectively) but not in women (β, −0.06; P = .57; β, 0.09; P = .49, respectively) with psoriasis.

Study details: The data come from a cross-sectional study of 232 patients with psoriasis and without known cardiovascular disease, of which 92 were women.

Disclosures: The study was supported by National Heart, Lung, and Blood Institute Intramural Research Program (Bethesda, Maryland). Dr. Mehta declared being a current full-time U.S. government employee and receiving a research grant from various sources. Dr. Khera declared serving as a scientific advisor and receiving speaker fees from various sources.

Source: Teklu M et al. Am J Prev Cardiol. 2021 Aug 22. doi: 10.1016/j.ajpc.2021.100231.

Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.